Castle Creek Pharmaceuticals, LLC
Castle Creek Biosciences, Inc. is a late-stage company focused on developing re-dosable gene therapies for genetic diseases. It conducts clinical trials for its lead candidate, D-Fi, for patients with dystrophic epidermolysis bullosa, and aims to create transformative therapies to improve lives. The company is involved in research collaborations, has a pipeline of products, and has received funding and grants to support its development efforts.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Personalized gene therapy pipeline for rare genetic diseases
A pipeline of personalized gene and cell therapy programs targeting rare and serious genetic diseases, encompassing both ex vivo autologous cell therapy candidates and in vivo viral-vector programs progressing through preclinical and pivotal clinical stages.
Autologous fibroblast cell therapy platform
A technology platform for autologous fibroblast-based therapeutic products used as a basis for ex vivo gene therapy development.
In vivo lentiviral gene therapy preclinical program
Preclinical in vivo gene therapy program using lentiviral vector delivery demonstrated in large-animal disease models and reported in peer-reviewed publication.
Personalized gene therapy pipeline for rare genetic diseases
A pipeline of personalized gene and cell therapy programs targeting rare and serious genetic diseases, encompassing both ex vivo autologous cell therapy candidates and in vivo viral-vector programs progressing through preclinical and pivotal clinical stages.
Autologous fibroblast cell therapy platform
A technology platform for autologous fibroblast-based therapeutic products used as a basis for ex vivo gene therapy development.
In vivo lentiviral gene therapy preclinical program
Preclinical in vivo gene therapy program using lentiviral vector delivery demonstrated in large-animal disease models and reported in peer-reviewed publication.
Services
Collaborative research partnerships to expand therapeutic platforms and translate academic findings into development programs.
Design and execution of preclinical efficacy studies, including large-animal models and vector-based interventions, with capability to support peer-reviewed publication.
Operational support for advancing gene therapy candidates through registrational clinical trials, including pivotal Phase 3 study execution and engagement for orphan-designated programs.
Collaborative research partnerships to expand therapeutic platforms and translate academic findings into development programs.
Design and execution of preclinical efficacy studies, including large-animal models and vector-based interventions, with capability to support peer-reviewed publication.
Operational support for advancing gene therapy candidates through registrational clinical trials, including pivotal Phase 3 study execution and engagement for orphan-designated programs.
Expertise Areas
- Gene therapy development
- Ex vivo autologous cell therapy
- In vivo gene therapy
- Rare disease clinical development
Key Technologies
- Lentiviral vector delivery
- Autologous fibroblast cell therapy
- Ex vivo gene correction workflows
- In vivo viral vector gene therapy
News & Updates
Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa.
Castle Creek Biosciences was awarded an FDA orphan products development grant to support the pivotal Phase 3 study of FCX-007, an investigational gene therapy for recessive dystrophic epidermolysis bullosa.
Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa.
Castle Creek Biosciences was awarded an FDA orphan products development grant to support the pivotal Phase 3 study of FCX-007, an investigational gene therapy for recessive dystrophic epidermolysis bullosa.